NXTC vs OABI

NextCure, Inc. vs OmniAb, Inc. — Valuation Comparison 2026

NXTC

Biotechnology
NextCure, Inc.
Quality
4.5
out of 10
Value Trap
24
SAFE
Price
$6.40
Last close
Models
7/13
Active
VS

OABI

Biotechnology
OmniAb, Inc.
Quality
5.8
out of 10
Value Trap
26
LOW
Price
$2.72
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType NXTC Fair ValueNXTC Upside OABI Fair ValueOABI Upside
Bayesian DCF Intrinsic $3.41 -46.7% $0.58 -78.7%
First Chicago Scenario $17.10 +77.6% $0.45 -83.5%
ML-RIV Intrinsic $18.39 +187.4% $0.60 -76.3%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NXTC vs OABI — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NXTC vs OABI — Which Stock Is More Undervalued?

OABI scores higher with a 5.8/10 quality rating vs NXTC's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing NextCure, Inc. (NXTC) and OmniAb, Inc. (OABI) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NXTC currently trades at $6.40 with a QOC of 4.5/10, while OABI trades at $2.72 with a QOC of 5.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).